Affinity Asset Advisors LLC Reduces Position in Trevi Therapeutics, Inc. $TRVI

Affinity Asset Advisors LLC trimmed its holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) by 7.0% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,000,172 shares of the company’s stock after selling 150,000 shares during the period. Trevi Therapeutics accounts for about 1.2% of Affinity Asset Advisors LLC’s holdings, making the stock its 25th biggest holding. Affinity Asset Advisors LLC’s holdings in Trevi Therapeutics were worth $23,862,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Hilton Head Capital Partners LLC lifted its stake in Trevi Therapeutics by 32.6% in the 1st quarter. Hilton Head Capital Partners LLC now owns 4,250 shares of the company’s stock worth $51,000 after purchasing an additional 1,044 shares in the last quarter. AlphaCentric Advisors LLC grew its position in shares of Trevi Therapeutics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 23,970 shares of the company’s stock valued at $286,000 after purchasing an additional 1,303 shares in the last quarter. Kennedy Capital Management LLC grew its position in shares of Trevi Therapeutics by 2.4% in the fourth quarter. Kennedy Capital Management LLC now owns 56,269 shares of the company’s stock valued at $704,000 after purchasing an additional 1,336 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Trevi Therapeutics by 32.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,231 shares of the company’s stock valued at $78,000 after purchasing an additional 1,523 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its holdings in shares of Trevi Therapeutics by 2.1% in the fourth quarter. Oppenheimer & Co. Inc. now owns 100,698 shares of the company’s stock valued at $1,261,000 after purchasing an additional 2,030 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TRVI has been the topic of a number of recent research reports. Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday, May 20th. Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Friday, July 17th. D. Boral Capital reaffirmed a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research note on Friday, April 17th. Finally, Morgan Stanley restated an “overweight” rating and issued a $20.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $24.91.

Trevi Therapeutics Price Performance

Shares of NASDAQ TRVI opened at $17.53 on Friday. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -54.78 and a beta of 1.00. The stock’s 50-day moving average is $16.11 and its two-hundred day moving average is $13.50. Trevi Therapeutics, Inc. has a 1-year low of $6.55 and a 1-year high of $20.22.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Equities research analysts anticipate that Trevi Therapeutics, Inc. will post -0.47 earnings per share for the current fiscal year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.